Small-scale clinical studies have reported on drug interactions between caspofungin (CPFG) and calcineurin inhibitors in healthy subjects; however, little is known about these interactions in allogeneic haematopoietic cell transplantation (allo-HCT) patients.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• CPFG reduced the blood concentration of TAC in a small healthy population.
• CsA increased the blood concentration of CPFG in a small healthy population.
• There is no available data on the concomitant administration of CPFG and TAC in allo-HCT patients.
WHAT THIS STUDY ADDS
• CPFG did not affect the pharmacokinetics of TAC in allo-HCT patients.
• Although CPFG significantly increased CsA concentration in allo-HCT patients, the clinical impact was small.
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Since the administration of anti-fungal agents is often required for allogeneic haematopoietic cell transplantation (allo-HCT) recipients at risk of fungal infections [4] , it is necessary to elucidate their drug interactions with calcineurin inhibitors [5] . Regarding azoles, Mori et al. reported that voriconazole or itraconazole oral solutions interacted with calcineurin inhibitors in allo-HCT recipients [6, 7] . In contrast, a Phase I study in healthy subjects reported that caspofungin (CPFG) could potentially reduce whole blood area under the concentration-time curve (AUC) of tacrolimus (TAC) by up to 20% [8, 9] . The only two case series data in solid organ transplantation did not reveal the significant drug interactions between CPFG and TAC [10, 11] . However, no data are available regarding potential interactions in allo-HCT settings. In addition, a Phase I study in healthy volunteers reported that cyclosporin A (CsA) increased plasma AUC of CPFG by approximately 35% [12] , and some participants showed mild, transient increases in alanine aminotransferase (ALT) levels. Several previous reports described that co-administration did not significantly increase the risk of hepatotoxicity in Caucasians [10, 11, [13] [14] [15] [16] [17] [18] [19] . However, there is a paucity of data in Asian populations. Therefore, we retrospectively assessed drug interactions and safety profiles in allo-HCT recipients treated concomitantly with CPFG and TAC/CsA.
Patients and methods
Study design and patient selection
We investigated the safety and drug interactions in allo-HCT patients who received concomitant therapy with CPFG and intravenous or oral TAC/CsA at our institution between May 2012 and February 2016. All patients who had been treated with both CPFG and TAC/CsA concurrently for at least 1 day were included in this study. Of those, we also evaluated the drug interactions between CPFG and TAC/CsA in patients who had already received intravenous TAC/CsA prior to CPFG and had been treated with a steady dose of TAC/CsA. The patients who had received voriconazole or itraconazole immediately before or during administration of CPFG were excluded from the drug interaction analysis. Data collection and all assessments were performed by two investigators (M.N. and A.T.) without intervention from the attending physicians. This study was approved by the Human Subjects Review Committee at Osaka City University and signed informed consent was obtained from all patients.
Drug administration and evaluation of drug safety
All patients received intravenously CPFG at a dose of 50 mg daily following a loading dose of 70 mg. TAC was continuously infused, and CsA was administered intravenously twice daily every 12 h over 3 h or once daily over 10 h. With respect to the oral formulation, both drugs were administered twice daily every 12 h. The target levels for the intravenous injections and the trough levels for the oral administration of TAC were both 10-15 ng ml À1 . The target blood trough levels of CsA were 150-250 and 100-250 ng ml À1 for twice-daily and once-daily administration, respectively, and the levels were measured every 1 or 2 days. The following laboratory data were assessed just before and at 7 and 14 days after the beginning and end of the concomitant therapy: aspartate aminotransferase (AST), ALT, alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (γGTP), bilirubin (Bil) and serum creatinine (Cre) levels. The severity of toxicity was assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.
Determination of concentration/dose (C/D) ratio of TAC/CsA
Blood samples were drawn 2-3 h before the administration of intravenous CsA. Plasma concentrations of CsA were measured using the standard fluorescence polarization immunoassay method. Plasma concentrations of TAC were measured using affinity column-mediated immunoassay (ACMIA) before February 11, 2013, using chemiluminescent enzyme immunoassay (CLIA) from February 11, 2013 to June 30, 2014, and using electrochemiluminescence immunoassay (ECLIA) after that date. The plasma C/D ratio of TAC/CsA was calculated by dividing the measured plasma concentration of TAC/CsA (ng ml À1 ) by the total daily dose (mg kg À1 ) of each drug for every patient just before and 5-7
days after the start of the concomitant therapy.
Statistical methods
Wilcoxon signed-rank tests were used to compare changes in the TAC/CsA C/D ratio and the laboratory data before and after CPFG in each group. P-values of less than 0.05 were considered to be statistically significant. All statistical analyses and graph drawings were performed using GraphPad Prism ® version 5.02.
Results
Patients
A total of 91 consecutive cases were eligible for inclusion. Their baseline characteristics are shown in Table 1 . Of these, drug interaction analyses could be performed in 50 patients (34 with TAC and 16 with CsA). Blood concentrations of TAC were measured in each individual by the same methods (ACMIA, n = 6; CLIA, n = 7; ECLIA, n = 21) before and after CPFG administration.
The effect of CPFG administration on TAC/CsA C/D ratio
The changes in the C/D ratios of TAC and CsA are shown in Figure 1 . In the 34 evaluated patients, there were no Table 1 Baseline patient characteristics during the concomitant therapy with caspofungin and calcineurin inhibitors Umbilical cord blood 13 9
Stem cell sources for allo-HCT Bone marrow 18 7
Peripheral blood 32 12
Cord blood 13 9
Conditioning regimen
Myeloablative
21
Reduced intensity 41 7
(continues) statistically significant differences in the C/D ratios of TAC before and after CPFG (before: median, 575.6; range, 237.6-1747.5; after: median, 672.4; range, 304.3-1694.9; Wilcoxon signed-rank P = 0.200) ( Figure 1A ). However, the C/D ratio of CsA in a steady state slightly increased after the administration of CPFG, and was significantly higher than that before CPFG administration in the 16 evaluated patients (before: median, 62.8; range, 21.1-145.1; after: median 74.9; range, 28.8-162.9; Wilcoxon signed-rank P = 0.016) ( Figure 1B ). Since fluconazole could affect the pharmacokinetics of TAC [20] , we also assessed its influence. Twenty-three of 34 TAC patients and 12 of 16 CsA patients stopped fluconazole just before the initiation of CPFG. The median TAC C/D ratios increased from 553.5 to 611.3 (P = 0.37) and 607.8 to 837.4 (P = 0.28) in patients with or without prior fluconazole, respectively; for CsA, the values increased from 66.9 to 77.1 (P = 0.08) and 40.6 to 55.9 (P = 0.13), respectively.
Safety of concomitant use of CPFG and TAC
CPFG was discontinued in only one patient, because of increased AST and ALT levels. This hepatotoxicity was considered to be associated with sinusoidal obstruction syndrome or side effects of teicoplanin and CPFG. In 15 patients, liposomal amphotericin B (n = 11), voriconazole (n = 2), or micafungin (n = 2) were substituted for CPFG due to the lack of improvement in the clinical symptoms or signs, or because nodular shadows were newly detected by CT imaging. One patient died of primary disease during the concomitant therapy. Three patients discontinued CPFG because no evidence of fungal infection was detected. In one patient, an itraconazole oral solution was substituted for CPFG as prophylaxis. A total of 42 patients completed the CPFG course with improved fever or fungal infections.
Analyses of hepatotoxicity and nephrotoxicity in 63 cases revealed no statistically significant changes in AST, Once a day 0 7 continuous 55 0
Abbreviations: allo-HCT, allogeneic haematopoietic cell transplantation; HLA, human leukocyte antigens; GVHD, graft-vs.-host disease; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; γGTP, γ-glutamyl transpeptidase; Bil, bilirubin. a Indicates one patient with aplastic anaemia in the tacrolimus group and one patient with aplastic anaemia and one patient with chronic active Epstein-Barr virus infection in the cyclosporin A group. b Among 20 patients with grade II to IV acute GVHD in the tacrolimus group, eight patients had acute GVHD at the beginning of the study, and the other 12 developed acute GVHD during the course of concomitant therapy. Among seven patients with grade II to IV acute GVHD in the cyclosporin A group, four patients had acute GVHD at the beginning of the study, and the other three developed acute GVHD during the course of the concomitant therapy. c All five patients had chronic GVHD at the study entry. d Indicates elevation above the upper limit of normal AST or ALT or ALP or γGTP or Bil value prior to the concomitant therapy. This includes 18 patients with increased AST, 29 with increased ALT, 20 with increased ALP, 37 with increased γGTP, and one with increased Bil at the beginning of the study in the tacrolimus group, and seven patients with increased AST, 10 with increased ALT, three with increased ALP, 17 with increased γGTP, and one with increased Bil at the beginning of the study in the cyclosporin A group. e Indicates elevation beyond the upper limit of normal serum creatinine value prior to the concomitant therapy.
ALT, ALP, γGTP or Cre levels before and at the end of coadministration (P = 0.36, P = 0.31, P = 0.69, P = 0.80 and P = 0.86, respectively) ( Figure 2A ). While the median Bil level was significantly elevated (P = 0.01), it remained within the normal range. All adverse events, irrespective of causality, are recorded in Table 2 .
Safety of concomitant use of CPFG and CsA
No patients discontinued CPFG due to elevated liver function or renal function values. In seven patients, liposomal amphotericin B (n = 5) or voriconazole (n = 2) was substituted for CPFG due to persistent fever or for newly detected nodular shadow by CT imaging. Three patients stopped receiving CPFG due to lack of evidence of fungal infection. Two patients died during the concomitant therapy as a result of graft-vs.-host disease. Sixteen patients finished receiving CPFG following improvement in their fevers or fungal infections. Analyses of 28 cases of hepatotoxicity and nephrotoxicity revealed no statistically significant changes in AST, ALT, γGTP, Bil or Cre levels before and at the end of co-administration (P = 0.37, P = 0.64, P = 0.40, P = 0.96 and P = 0.57, respectively) ( Figure 2B ). While the median ALP level was significantly elevated (P = 0.01), it remained within the normal range.
Discussion
The present study demonstrated that CPFG did not affect the pharmacokinetics of TAC and that it could slightly increase the blood concentration of CsA in allo-HCT patients. These findings were inconsistent with previous reports [8, 9, 14, 15] . However, the drug interactions between CPFG and CsA did not appear to be clinically significant. In our study, CPFG had no significant impact on the plasma kinetics of intravenously-administered TAC, which were not influenced by prophylactic fluconazole. This nonsignificant finding is inconsistent with those in healthy volunteers [8] and consistent with the results in liver and lung transplant recipients [10, 11] . In light of the results of preclinical studies showing CPFG to be neither a significant substrate nor a potent inhibitor of P-glycoprotein or hepatic cytochrome enzymes [12, 20] , CPFG does not appear to significantly alter TAC pharmacokinetics. Therefore, drug interactions between CPFG and TAC do not appear to be a problem in allo-HCT patients.
Sanz-Rodriguez et al. reported that CPFG did not significantly impact the CsA pharmacokinetics in seven allo-HCT patients [14] . Their study included both oral and intravenous administration of CsA. However, heterogeneity in the administration route and/or small sample size may limit the interpretation of these data. Additionally, three studies concluded that there were no significant differences in CsA blood concentrations before and after coadministration of CPFG in three thoracic organ transplant, five liver transplant, and seven allo-HCT recipients (CsA concentration: mean 214-229, mean 113-190 and median 250-389 ng ml À1 , respectively) [10, 11, 18] . However, CsA concentrations were slightly or moderately elevated; these findings may be influenced by the lack of sample power. The data in the present study showed significantly increased CsA concentration. As the change seemed to be slower and smaller than that observed for voriconazole/itraconazole [6, 7] , the attending physicians were able to clinically manage CsA blood levels by routine monitoring. We did not identify the reasons for the elevated CsA concentrations. CPFG is metabolized by nonenzymatic hydrolysis and is not significantly associated with cytochrome P450 systems [12, 21] . In contrast, in vitro data showed that CPFG inhibits CYP450 3A4 [22] . In addition, there could be ethnic differences in CYP3A4-mediated drug metabolism [20, 23] . As CsA is a known substrate of CYP450 3A4 [24] , it is possible that CPFG interacts with CsA via CYP450 3A4 in the Japanese population. Further research is needed to elucidate the metabolic pathway of CPFG, including the influence of ethnic differences.
In healthy volunteers, CsA had significant effects on the pharmacokinetics of CPFG and a mild transient elevation of ALT level was observed [12] . It has been thought that the inhibition of organic anion transporting polypeptide caused by CsA reduces the uptake of CPFG into hepatocytes; the subsequent increase in CPFG blood concentration could result in increased ALT levels [25] . However, the current study observed no statistically significant differences in liver or renal functions. Although there were statistically significant mild elevations of Bil and ALP levels in the TAC and CsA groups, they remained within the normal ranges; therefore, these increases were not considered indicative of clinically significant impacts. Consistent with previous reports [10, 11, [13] [14] [15] [16] [17] [18] [19] , the results of our study suggest that combination therapy was mostly safe in allo-HCT recipients. Table 2 Laboratory test profiles on hepatotoxicity and nephrotoxicity during the concomitant therapy with caspofungin and calcineurin inhibitors 
Abbreviations: allo-HCT, allogeneic haematopoietic cell transplantation; HLA, human leukocyte antigens; GVHD, graftversus-host disease; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; γGTP, γ-glutamyl transpeptidase; Bil, bilirubin; Cre, serum creatinine. a The patient developed grade 4 elevation in Bil due to acute graftvs.-host disease.
Caspofungin drug interaction in transplantation
This study may be limited by its retrospective design and small study population. While previous studies with a similar sample size showed significant drug interactions between TAC/CsA and voriconazole/itraconazole, in this study, CPFG had a smaller effect on TAC pharmacokinetics compared to that of voriconazole/itraconazole [6, 7] . Another limitation was that our study included patients with CsA administered at different intervals (once or twice daily). However, these different intervals did not seem to affect the comparisons of C/D ratios as they were performed for individual patients with the same intervals of administration. Finally, although unknown or unmeasured confounding variables might account for the significant interaction between CPFG and CsA, we did not find obvious confounding factors in the current study.
In conclusion, the current data suggest that the drug interactions between CPFG and TAC were not clinically significant. In addition, we could keep constant CsA levels under regular blood concentration monitoring during coadministration with CPFG, even though CPFG could mildly increase CsA concentration.
